BridgeBio Pharma, Inc. — Director's Dealing 2024

Mar 5, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-03-01

Reporting Person: Scott Randal W. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-03-01	Common Stock	S	2500	$34.00	Disposed	6500	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5000	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023.